Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: YASMIN Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous Versus Cyclical OCP Use in PCOS

NCT03819140
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Yasmin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

NCT06820307
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Not applicable Interventional Results available

The Oral Contraceptive Pill for Premenstrual Worsening of Depression

NCT00633360
View directory record Official record
Conditions
Premenstrual Syndrome, Depression
Interventions
Drospirenone and ethinyl estradiol, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 2, 2026, 4:22 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

NCT00722800
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
drospirenone and ethinyl estradiol (YAZ), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

NCT00640224
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
rosiglitazone, drospirenone/ethinyl estradiol
Drug
Lead sponsor
Silva Arslanian
Other
Eligibility
10 Years to 20 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

NCT00567164
View directory record Official record
Conditions
Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions
EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,887 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
85
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

NCT00722761
View directory record Official record
Conditions
Acne Vulgaris
Interventions
drospirenone and ethinyl estradiol, Placebo tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

NCT01254292
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 29 Years · Female only
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
24
States / cities
Tucson, Arizona • La Mesa, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 2, 2026, 4:22 PM EDT
Terminated Phase 2 Interventional Results available

Binge Eating & Birth Control

NCT04278755
View directory record Official record
Conditions
Bulimia Nervosa, Binge Eating, Eating Disorders, Binge-Eating Disorder
Interventions
Drospirenone-Ethinyl Estradiol Oral Tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

NCT00420342
View directory record Official record
Conditions
Postmenopause, Hypertension, Pre-Hypertension
Interventions
Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Not applicable Interventional Results available

Metabolic Syndrome in PCOS: Precursors and Interventions

NCT00442689
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Metabolic Syndrome
Interventions
flutamide, ethinyl estradiol 35 mcg and drospirenone 3 mg, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

NCT00651469
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

NCT01182207
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

NCT00283816
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo
Drug · Behavioral · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

NCT01182194
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

NCT01291004
View directory record Official record
Conditions
Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size, Oral Contraceptive
Interventions
Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne

NCT00656981
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
22
States / cities
Mobile, Alabama • Kingman, Arizona • Encino, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants

NCT02885454
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/ethinylestradiol, AL-335, Odalasvir (ODV), Simeprevir (SMV)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 4 Interventional Results available

Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)

NCT00927095
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder
Interventions
Continuous OC (EE/DROS), Intermittent OC (EE/DROS), placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

NCT06250205
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC)
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 4:22 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

NCT00089414
View directory record Official record
Conditions
Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
Interventions
Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function

NCT01109979
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Estradiol+MPA, Estradiol+Drospirenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 2, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

NCT07074327
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 2, 2026, 4:22 PM EDT